Stockscreener 앱 받기
3.75
5.54%
-0.22
전일 마감가:
$3.97
열려 있는:
$4.01
하루 거래량:
2.29M
Relative Volume:
1.48
시가총액:
$559.06M
수익:
$181.41M
순이익/손실:
$-59.56M
주가수익비율:
-8.9286
EPS:
-0.42
순현금흐름:
$-38.83M
1주 성능:
+4.46%
1개월 성능:
+12.28%
6개월 성능:
+32.04%
1년 성능:
+25.00%
1일 변동 폭
$3.69
$4.0103
1주일 범위
$3.5599
$4.10
52주 변동 폭
$1.69
$4.10
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
3.75 | 559.06M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Still a Buy? - Defense World
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month HighStill a Buy? - MarketBeat
Xeris Pharmaceuticals stock hits 52-week high of $3.87 - Investing.com India
Xeris Pharmaceuticals stock hits 52-week high of $3.87 By Investing.com - Investing.com South Africa
Legato Capital Management LLC Purchases Shares of 142,164 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Raised by Janney Montgomery Scott LLC - Defense World
Take off with Xeris Biopharma Holdings Inc (XERS): Get ready for trading - SETE News
Xeris Biopharma Holdings Inc [XERS] Shares Fall -1.36 % on Thursday - Knox Daily
Omnicell, Inc [OMCL] Records 50-Day SMA of $44.59 - Knox Daily
Stock Performance Spotlight: Xeris Biopharma Holdings Inc (XERS) Ends the Day at 3.64, Up by 1.39 - The Dwinnex
Xeris to Participate in Upcoming Investor Conferences - BioSpace
A year in review: Xeris Biopharma Holdings Inc (XERS)’s performance in the last year - US Post News
SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Perhaps timely catching Xeris Biopharma Holdings Inc (XERS) would be a good idea - SETE News
Piper Sandler downgrades Xeris Biopharma Holdings Inc (XERS) rating to a Neutral - Knox Daily
Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio - Simply Wall St
JPMorgan Chase & Co. Acquires 67,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Down -1.47% This Year: What To Expect Next - Stocks Register
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness - Beloit Daily News
ADA Partners With Xeris to Combat Rising Diabetes Emergency Cases Amid 202,000 Annual ER Visits - StockTitan
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than -103.7% - Stocks Register
Barclays PLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M - MSN
Arecor stock plummets after Tetris retreat - Business Weekly
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7%Here's Why - MarketBeat
Xeris Expects to Exceed Full-Year 2024 Financial Guidance - BioSpace
Xeris Biopharma exceeds 2024 revenue guidance - Investing.com India
Xeris Biopharma Exceeds 2024 Guidance with $203M Revenue, Posts Record Q4 Growth - StockTitan
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Position Lifted by Principal Financial Group Inc. - Defense World
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 6, 2025 - BioSpace
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Geode Capital Management LLC - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Jane Street Group LLC - Defense World
Barclays PLC Purchases 151,685 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
State Street Corp Sells 53,915 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - The Manila Times
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2%What's Next? - MarketBeat
Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Walleye Capital LLC Purchases Shares of 1,121,738 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $237,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
XERS (Xeris Biopharma Holdings) Revenue : $187.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Xeris Biopharma Holdings (FRA:2B30) Other Long Term Assets : €4.9 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Other Stockholders Equity : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) EPS (Diluted) : $-0.44 (TTM As of Sep. 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) GF Score : 75/100 (As of Nov. 26, 2024) - GuruFocus.com
XERS (Xeris Biopharma Holdings) Accounts Payable : $7.5 Mil (As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference - Business Wire
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xeris Biopharma Holdings Inc 주식 (XERS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Aug 12 '24 |
Buy |
2.25 |
4,515 |
10,147 |
25,200 |
| Schmid John P. | Director |
Aug 09 '24 |
Buy |
2.37 |
4,285 |
10,134 |
20,685 |
| Schmid John P. | Director |
May 10 '24 |
Buy |
1.91 |
5,400 |
10,314 |
16,400 |
| JOHNSON JOHN | Director |
Mar 18 '24 |
Option Exercise |
1.99 |
215,600 |
429,044 |
751,412 |
| Schmid John P. | Director |
Mar 14 '24 |
Buy |
2.16 |
4,500 |
9,720 |
11,000 |
0.27%
3.05%
자본화:
|
볼륨(24시간):